title: Use of gonadotropin-releasing hormone agonists in patients with Hodgkin's disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy.
abstract: In young women receiving chemotherapy for Hodgkin's disease, the combined use of triptorelin and tibolone cotreatment may be a useful tool for preserving ovarian function because all but three (10%) of the women in this treatment group returned to spontaneous ovulation and menses, in contrast to 23% of subjects in the control group (P<.05). No significant differences were observed in bone mineral density between groups.
authors.forename: Camil
authors.initials: C
authors.lastname: Castelo-Branco
authors.forename: Benet
authors.initials: B
authors.lastname: Nomdedeu
authors.forename: Adela
authors.initials: A
authors.lastname: Camus
authors.forename: Santiago
authors.initials: S
authors.lastname: Mercadal
authors.forename: María Jesús
authors.initials: MJ
authors.lastname: Martínez de Osaba
authors.forename: Juan
authors.initials: J
authors.lastname: Balasch
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects; D001761:Bleomycin / Q000008:administration & dosage / Q000009:adverse effects; D015519:Bone Density / Q000187:drug effects; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000009:adverse effects; D003606:Dacarbazine / Q000008:administration & dosage / Q000009:adverse effects; D004317:Doxorubicin / Q000008:administration & dosage / Q000009:adverse effects; D005260:Female; D007987:Gonadotropin-Releasing Hormone / Q000819:agonists*; D006689:Hodgkin Disease / Q000188:drug therapy*; D006801:Humans; D009652:Norpregnenes / Q000627:therapeutic use*; D010053:Ovary / Q000502:physiology; D011241:Prednisone / Q000008:administration & dosage / Q000009:adverse effects; D016649:Primary Ovarian Insufficiency / Q000139:chemically induced* / Q000517:prevention & control*; D011344:Procarbazine / Q000008:administration & dosage / Q000009:adverse effects; D017329:Triptorelin Pamoate / Q000627:therapeutic use*; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000970:Antineoplastic Agents; D009652:Norpregnenes; D017329:Triptorelin Pamoate; D001761:Bleomycin; D007987:Gonadotropin-Releasing Hormone; D011344:Procarbazine; D014750:Vincristine; D014747:Vinblastine; D003606:Dacarbazine; D004317:Doxorubicin; D003520:Cyclophosphamide; C027385:tibolone; D011241:Prednisone